Reply to Correspondence: Response to a case report: idiopathic hypereosinophilic syndrome in remission with benralizumab treatment after relapse with mepolizumab

See related Letter

Detalles Bibliográficos
Autores principales: Fujii, Koki, Takahashi, Hidenori, Hayakawa, Nami, Iwasaki, Yoshinobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2021
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788443/
https://www.ncbi.nlm.nih.gov/pubmed/33437491
http://dx.doi.org/10.1002/rcr2.708
_version_ 1783633034529996800
author Fujii, Koki
Takahashi, Hidenori
Hayakawa, Nami
Iwasaki, Yoshinobu
author_facet Fujii, Koki
Takahashi, Hidenori
Hayakawa, Nami
Iwasaki, Yoshinobu
author_sort Fujii, Koki
collection PubMed
description See related Letter
format Online
Article
Text
id pubmed-7788443
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley & Sons, Ltd
record_format MEDLINE/PubMed
spelling pubmed-77884432021-01-11 Reply to Correspondence: Response to a case report: idiopathic hypereosinophilic syndrome in remission with benralizumab treatment after relapse with mepolizumab Fujii, Koki Takahashi, Hidenori Hayakawa, Nami Iwasaki, Yoshinobu Respirol Case Rep Correspondence See related Letter John Wiley & Sons, Ltd 2021-01-07 /pmc/articles/PMC7788443/ /pubmed/33437491 http://dx.doi.org/10.1002/rcr2.708 Text en © 2021 The Authors. Respirology Case Reports published by John Wiley & Sons Australia, Ltd on behalf of The Asian Pacific Society of Respirology This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Correspondence
Fujii, Koki
Takahashi, Hidenori
Hayakawa, Nami
Iwasaki, Yoshinobu
Reply to Correspondence: Response to a case report: idiopathic hypereosinophilic syndrome in remission with benralizumab treatment after relapse with mepolizumab
title Reply to Correspondence: Response to a case report: idiopathic hypereosinophilic syndrome in remission with benralizumab treatment after relapse with mepolizumab
title_full Reply to Correspondence: Response to a case report: idiopathic hypereosinophilic syndrome in remission with benralizumab treatment after relapse with mepolizumab
title_fullStr Reply to Correspondence: Response to a case report: idiopathic hypereosinophilic syndrome in remission with benralizumab treatment after relapse with mepolizumab
title_full_unstemmed Reply to Correspondence: Response to a case report: idiopathic hypereosinophilic syndrome in remission with benralizumab treatment after relapse with mepolizumab
title_short Reply to Correspondence: Response to a case report: idiopathic hypereosinophilic syndrome in remission with benralizumab treatment after relapse with mepolizumab
title_sort reply to correspondence: response to a case report: idiopathic hypereosinophilic syndrome in remission with benralizumab treatment after relapse with mepolizumab
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788443/
https://www.ncbi.nlm.nih.gov/pubmed/33437491
http://dx.doi.org/10.1002/rcr2.708
work_keys_str_mv AT fujiikoki replytocorrespondenceresponsetoacasereportidiopathichypereosinophilicsyndromeinremissionwithbenralizumabtreatmentafterrelapsewithmepolizumab
AT takahashihidenori replytocorrespondenceresponsetoacasereportidiopathichypereosinophilicsyndromeinremissionwithbenralizumabtreatmentafterrelapsewithmepolizumab
AT hayakawanami replytocorrespondenceresponsetoacasereportidiopathichypereosinophilicsyndromeinremissionwithbenralizumabtreatmentafterrelapsewithmepolizumab
AT iwasakiyoshinobu replytocorrespondenceresponsetoacasereportidiopathichypereosinophilicsyndromeinremissionwithbenralizumabtreatmentafterrelapsewithmepolizumab

Ejemplares similares